OPK
OPKO Health, Inc. · NASDAQ
- Sector Health Services
- Industry Medical/Nursing Services
- Website opko.com
- Employees(FY) 4196
- ISIN US68375N1037
Performance
+4.23%
1W
-1.99%
1M
+9.63%
3M
+13.85%
6M
-1.99%
YTD
+10.45%
1Y
Profile
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Technical Analysis of OPK 2024-11-04
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-01 07:10
- 2024-10-29 16:05
- 2024-10-29 04:05
- 2024-10-17 07:59
- 2024-10-11 09:18
- 2024-10-07 08:37
- 2024-10-07 08:29
- 2024-10-07 08:00
- 2024-10-07 08:00
- 2024-10-06 20:00
- 2024-10-06 20:00
- 2024-10-02 11:54
- 2024-09-26 12:51
- 2024-09-25 08:30
- 2024-09-24 20:30
- 2024-09-23 08:00
- 2024-09-22 20:00
- 2024-09-16 07:30
- 2024-09-15 19:30
- 2024-08-09 16:05
- 2024-08-09 04:05
- 2024-08-08 12:14
- 2024-08-08 09:14
- 2024-08-08 00:15
Opko Health (OPK) Q2 2024 Earnings Call Transcript(Motley Fool)
- 2024-08-07 20:00
- 2024-08-07 18:59
OPKO Health: Q2 Earnings Snapshot(Associated Press Finance)
- 2024-08-07 16:06
- 2024-08-07 04:06
- 2024-08-01 16:05
- 2024-08-01 04:05
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.